StandardX Raises £10 Million to Build Scalable Isotope Refinery for Medicine and Fusion Energy
StandardX, a UK-headquartered European deep technology company founded in 2025, has raised £10 million in seed funding to develop what it describes as the world’s first scalable isotope refinery. The company aims to significantly expand the production of rare isotopes used across advanced medicine, cancer diagnosis and treatment, and emerging energy technologies such as nuclear fusion.
The funding round was led by Vsquared Ventures and East X Ventures, with additional participation from firstminute capital, the UK Innovation and Science Seed Fund (UKI2S), Brevan Howard Macro Venture and Geometry. The investment will support StandardX as it moves from early-stage technology development toward engineering, site establishment and pilot isotope production.
Isotopes are forms of chemical elements that contain the same number of protons but differ in their number of neutrons. Their specific physical and chemical characteristics make them important materials for a wide range of applications, including medical imaging, cancer therapies, scientific research and nuclear energy.
However, the supply of many commercially important isotopes remains constrained. Production is concentrated in a relatively small number of facilities, while much of the existing infrastructure is specialized, ageing or limited in capacity. StandardX is seeking to address these limitations by developing a flexible production platform capable of manufacturing multiple isotopes using a standardized accelerator-based system.
Addressing Isotope Supply Constraints in Healthcare
One of the company’s primary areas of focus is medical isotopes, particularly those required for cancer diagnosis and treatment.
Radiopharmaceuticals use radioactive isotopes to help identify disease or deliver therapeutic radiation to specific tissues. In oncology, advances in targeted radiopharmaceutical therapies have created growing demand for isotopes capable of delivering radiation directly to cancer cells.
Targeted alpha therapies are one example of this emerging approach. These treatments use alpha-emitting isotopes to deliver highly localized radiation to cancer cells while limiting exposure to surrounding healthy tissue. As research and clinical development progress, reliable access to the necessary isotopes has become an important component of the broader radiopharmaceutical supply chain.
StandardX argues that existing isotope production capacity is not sufficiently flexible or scalable to meet both current medical requirements and potential future demand. The company intends to develop infrastructure that can supply isotopes for hospitals and medical researchers today while also supporting pharmaceutical developers working on treatments that may require isotopes not yet available commercially at meaningful scale.
The company’s initial production program will therefore focus on isotopes used in cancer diagnosis and therapy. StandardX expects to provide its first isotopes to a medical research partner in 2027.
The company’s expansion plans come against a backdrop of continued pressure on cancer care systems. In the UK, Cancer Research UK reported that only 69.6% of patients received treatment within 62 days of an urgent referral in May 2026, compared with the national target of 85%. The target has not been achieved since December 2015. Although isotope availability represents only one element of the broader cancer-care system, StandardX sees resilient access to critical medical materials as part of the infrastructure required to support future cancer diagnostics and treatments.
A Flexible Accelerator-Based Refinery
At the center of StandardX’s strategy is its proprietary accelerator technology.
Traditional isotope production often relies on specialized facilities and equipment designed around particular isotopes or production processes. StandardX is developing a system intended to replace this fragmented approach with a more standardized and flexible production platform.
According to the company, its accelerator system will be capable of producing a broad portfolio of isotopes at commercial scale. The systems are designed to operate on a standard industrial footprint and could potentially be deployed in different locations according to regional demand.
This distributed approach could allow isotope production to be located closer to hospitals, research institutions, pharmaceutical companies and other end users. StandardX believes this could reduce dependence on a small number of geographically concentrated production facilities and create a more resilient supply network.
The company’s objective extends beyond increasing overall production. By developing a platform that can be adapted to different isotope requirements, StandardX aims to provide infrastructure that can evolve alongside advances in medical research.
This flexibility could be particularly relevant as radiopharmaceutical development expands. New therapies can create demand for specific isotopes, but establishing dedicated production infrastructure for every new isotope can be challenging. A broader production platform could potentially allow manufacturers to respond more quickly to changing requirements.
Expansion Into Nuclear Fusion
Although healthcare will be the company’s initial market, StandardX plans to apply the same accelerator platform to other industries.
One of the company’s longer-term targets is tritium, a radioactive isotope of hydrogen that is expected to play an important role in some fusion-energy technologies. Tritium is used as a fuel component in several fusion concepts, including approaches based on deuterium-tritium reactions.
Tritium availability is currently extremely limited. StandardX states that only about 25 kilograms of tritium exists globally today, while a single fusion power plant could ultimately require tens of kilograms annually.
The anticipated growth of fusion energy therefore creates a potential future requirement for new tritium production and supply infrastructure. StandardX has already signed agreements with fusion developers to manufacture tritium in support of their efforts to develop fusion power.
The company is consequently pursuing two related markets: medical isotopes that have an immediate and growing need, and industrial isotopes that could become increasingly important as advanced energy technologies scale.
This strategy also allows StandardX to develop its isotope platform without depending exclusively on the commercial timetable for fusion energy.
Building a European Supply Chain
StandardX was co-founded in 2025 by Richard Pearson, who serves as CEO, and Ross Allen, who serves as CTO. Both are nuclear engineers with experience in technology development and startup scaling.
The founders established StandardX with the goal of creating a more reliable and resilient supply chain for rare and strategically important materials in Europe.
Since its launch, the company has assembled a team of 15 scientists, engineers and operators with experience across organizations and institutions including SpaceX, The London Clinic, the University of Oxford, the University of Cambridge, Fermilab and the UK Atomic Energy Authority.
The newly raised £10 million will be used to expand this team and secure StandardX’s first industrial site in London. The company plans to deploy its first accelerator-based isotope refinery at the site and advance the engineering and construction of the system.
StandardX expects pilot isotope production to begin in 2027, with material distributed to a medical research partner. The company is targeting industrial-scale production from 2029.
Richard Pearson, CEO and co-founder of StandardX, said that isotope supply constraints affect several industries, with shortages particularly significant in cancer medicine. He also pointed to projections that global cancer cases could increase substantially by 2050, arguing that infrastructure capable of supporting future isotope demand will become increasingly important.
“Isotopes underpin the next era of innovation across several key sectors, but all share the same constraints around supply,” Pearson said. He added that StandardX is developing a platform intended to address those supply limitations.
Ross Allen, CTO and co-founder, said the latest funding represents a transition from the company’s initial concept toward engineering and hardware development.
“StandardX began with a problem: isotope supply limited by legacy infrastructure,” Allen said. He explained that the company’s immediate focus is its planned London industrial site, where the first isotope refinery system will be deployed and developed in collaboration with clinicians and researchers.
Investor Support for Isotope Infrastructure
Investors participating in the seed round highlighted both the immediate medical applications and potential longer-term opportunities in energy.
Lise Rechsteiner, General Partner at Vsquared Ventures, said the radiopharmaceutical sector is approaching an important stage of development but that isotope production has not expanded at the same pace. She described StandardX’s platform as flexible enough to support both currently required isotopes and those that could be needed for future cancer treatments.
Theodore Mollinger, General Partner at EastX, similarly highlighted the company’s dual-market strategy. He noted that StandardX can initially build its business around medical isotope demand while maintaining the potential to address tritium supply requirements if fusion energy expands.
The funding gives StandardX capital to move beyond technology development and establish the physical infrastructure required for commercial isotope production. Over the coming years, the company plans to progress from its first industrial installation and pilot manufacturing to larger-scale production.
StandardX’s roadmap reflects a broader effort to strengthen supply chains for specialized materials that are increasingly important to advanced healthcare and energy technologies.
In the near term, the company is concentrating on medical isotopes for cancer diagnosis and treatment. Its planned 2027 pilot production will provide an early test of its accelerator-based refinery and its ability to supply material to a medical research partner.
The longer-term objective is industrial-scale isotope production beginning in 2029, followed by expansion into additional applications, including tritium for fusion energy.
If the company achieves its development milestones, its standardized refinery model could provide an alternative to highly specialized and geographically concentrated isotope production infrastructure. The approach is intended to create a supply platform capable of adapting to changing demand across medicine, research and advanced energy.
With the £10 million seed financing, StandardX is now moving into the engineering and deployment phase of its development. Its progress will be closely tied to the successful construction and operation of its first refinery, validation of its isotope production capabilities, and establishment of partnerships with medical and energy customers.
For the radiopharmaceutical industry, the company’s initial focus addresses a fundamental requirement: access to the isotopes needed to develop and deliver next-generation diagnostic and therapeutic technologies. For the emerging fusion sector, the same underlying production technology could eventually address one of the industry’s critical material requirements.
StandardX is therefore positioning its isotope refinery platform as infrastructure designed not for a single isotope or application, but for a broader generation of technologies that depend on reliable access to rare radioactive materials.
About StandardX
StandardX makes the rarest materials on Earth, the ones medicine, fusion energy and other advanced industries depend on. The company is building the world’s first isotope refinery, an accelerator system capable of scaling supply of the full portfolio of isotopes wherever it is deployed. A European deep tech company based in the UK, StandardX is unlocking the path to a resilient global supply of rare critical materials. Turning scarcity into abundance, starting with the materials behind cancer care.
About Vsquared Ventures
Vsquared Ventures backs bold entrepreneurs engineering groundbreaking technologies addressing some of the world’s most pressing challenges to become global leaders. Investing in deep tech companies, Vsquared Ventures focuses on new space, energy transition, robotics and manufacturing, new computing and sensing, AI and next-gen software and tech-bio. Vsquared Ventures has built one of Europe’s strongest deep tech portfolios, including industry disruptors Isar Aerospace, IQM Quantum Computing, Zama.ai, Neura Robotics, Cylib and The Exploration Company. www.vsquared.vc
About EastX
East X Ventures is the venture capital arm of East X, a London-based quantitative commodities investment firm managing several billion dollars in assets. The firm invests in founders transforming frontier science into commercially scalable companies across fusion energy, next-generation power systems, supply chains and artificial intelligence. Backed by the UK Atomic Energy Authority and the UK Department for Energy Security and Net Zero, East X Ventures launched Starmaker One, Europe’s first dedicated venture capital fund focused on fusion energy.